As part of its quarterly cleaning, Eli Lilly removed a few trials from its pipeline, including late-stage studies of approved cancer drug Verzenio and its Boehringer Ingelheim-partnered drug Jardiance.

The Indianapolis-based pharma giant also removed a Phase 2 trial of a gene therapy it got through the $1 billion-plus acquisition of Prevail Therapeutics a few years ago. Also out the door is an undisclosed Phase 1 immunology asset, per the company’s first-quarter earnings presentation.

The moves come as Lilly ramped up its R&D spending in the first quarter to $2.52 billion, a 27% increase. It’s also still working through supply hurdles for its diabetes and obesity medications. The potential of the drugs, known as Mounjaro and Zepbound, have propelled Lilly to the largest pharmaceutical company in the world by market capitalization.

Lilly’s share price $LLY was up nearly 7% in Tuesday morning trading.

On the Verzenio front, Lilly said it culled the Phase 3 CYCLONE-3 trial of the cancer drug in patients with hormone sensitive prostate cancer due to futility. The company said it took an approximately $75 million charge in the first quarter due to the prostate cancer program termination.

The move adds to a recent string of disappointments for Verzenio. Earlier this year, Lilly also scrapped a late-stage study of the medicine in patients with castration-resistant prostate cancer after it failed to improve progression-free survival. The CDK4/6 inhibitor also missed an overall survival endpoint in advanced breast cancer last December.

Meanwhile, Lilly removed a Phase 3 test of its type 2 diabetes and heart failure drug Jardiance, which it markets with Boehringer Ingelheim. The drug failed the EMPACT-MI study earlier this month, Boehringer reported. Jardiance was not better than placebo at lowering the chances of going to the hospital due to heart failure or all-cause mortality, with just a 10% relative risk reduction shown in the study, Boehringer said April 6.

For the Prevail-acquired GBA1 gene therapy, Lilly said it pulled a Phase 2 study testing the asset in patients with Gaucher disease type 2. The fatal disease disrupts a baby’s brain and causes an enlarged liver and spleen, among other impacts.

Lilly is still testing the gene therapy, known as LY3884961 (formerly PR001), in patients with Gaucher type 1 and Parkinson’s disease with at least one GBA1 mutation. The PROCEED and PROPEL trials, respectively, are still recruiting, as of recent updates to their listing.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.